TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25878177

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-EIAEDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EIAEDs
Number of subjects: 0
Study: 23306584

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (approximately 3 ml/kg) combined with extracorporeal CO2 elimination
Number of subjects: 79

Group type: COMPARATOR
Intervention: ARDSNet strategy (approximately 6 ml/kg) without the extracorporeal device
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study: 22009805

Group type: EXPERIMENTAL
Intervention: Atracourium (5 mg in 0.5 ml)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: cis-Atracourium (5 mg in 0.5 ml)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (0.5 ml normal saline)
Number of subjects: 90
Study: 20467603

Group type: EXPERIMENTAL
Intervention: 5-mm-long Rescue implants (Megagen)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10-mm-long implants placed in augmented bone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Augmented group (10-mm-long implants)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 16914693

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNB-1b) 250 mug subcutaneously every other day (EOD)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 16003621

Group type: COMPARATOR
Intervention: Conventional maxillomandibular fixation (MMF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Short period of maxillomandibular fixation (MMF) for 2 weeks followed by an arch bar splint wired to the lower jaw
Number of subjects: 30
Study: 11862577

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 3991

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3991
Study: 10187875

Group type: EXPERIMENTAL
Intervention: Intraparenchymal hemorrhages
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Extraparenchymal bleeding
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Cerebral edema
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Large hematoma with concomitant extraparenchymal bleeding
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Hemorrhagic infarction with cerebral edema
Number of subjects: 554
Study: 7709928

Group type: EXPERIMENTAL
Intervention: Osteoporosis therapy (specific intervention details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (no specific control group mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (no specific intervention mentioned)
Number of subjects: 0
Study: 2311147

Group type: EXPERIMENTAL
Intervention: Propofol (2.0‐2.5 mg.kg‐1 followed by a continuous infusion 0.1‐0.2 mg.kg‐1.min‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone (4.0‐5.0 mg.kg‐1, infusion rate 0.16‐0.32 mg.kg‐1.min‐1)
Number of subjects: 60
Study: 6107500

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus levamisole 2.5 mg/kg/day for two consecutive days each week for 48 weeks
Number of subjects: 720

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus levamisole
Number of subjects: 720
Study: 30915431

Group type: EXPERIMENTAL
Intervention: Educational intervention based on health belief model (HBM) and collaborative learning techniques
Number of subjects: 311

Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned)
Number of subjects: 311
Study: 27757829

Group type: EXPERIMENTAL
Intervention: Probiotic soy milk containing Lactobacillus planetarum A7
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pure soy milk (control)
Number of subjects: 40
Study: 26400963

Group type: EXPERIMENTAL
Intervention: Baked beef meal
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baked herring meal
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pickled herring meal
Number of subjects: 17
Study: 23937012

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 60
Study: 22032120

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (64 microg per, 256 microg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline nasal spray (twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study: 20069203

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nortriptyline (20 mg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of Propranolol and Nortriptyline (40 mg and 20 mg per day respectively)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Nortriptyline alone)
Number of subjects: 30
Study: 17684553

Group type: EXPERIMENTAL
Intervention: Advice book on LBP (the 'back book')
Number of subjects: 2752

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2752
Study: 15139978

Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg weekly)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 11838927

Group type: EXPERIMENTAL
Intervention: Short duration antibiotic prophylaxis (2 days)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Long duration antibiotic prophylaxis (7 days)
Number of subjects: 178
Study: 9521829

Group type: EXPERIMENTAL
Intervention: Remember responses
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Know responses
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Guess responses
Number of subjects: 270
Study: 7922057

Group type: EXPERIMENTAL
Intervention: Helium pneumoperitoneum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Carbon dioxide pneumoperitoneum
Number of subjects: 60
Study: 3383994

Group type: EXPERIMENTAL
Intervention: l-carnitine 20 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: l-carnitine 40 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: l-carnitine 60 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: l-carnitine infusion
Number of subjects: 10
Study: 31542965

Group type: EXPERIMENTAL
Intervention: Visit-to-visit BPV (highest quartile)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Day-to-day BPV
Number of subjects: 460
Study: 29185106

Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 264
Study: 27654729

Group type: EXPERIMENTAL
Intervention: Topical finasteride 0.5%
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 104
Study: 24641712

Group type: EXPERIMENTAL
Intervention: Cerebral palsy (no specific intervention mentioned)
Number of subjects: 594
Study: 22904030

Group type: EXPERIMENTAL
Intervention: Extended-release memantine
Number of subjects: 676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study: 22253996

Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Number of subjects: 58

Group type: COMPARATOR
Intervention: High glycemic index diet
Number of subjects: 58
Study: 17355732

Group type: EXPERIMENTAL
Intervention: Cilastatin co-administered with cyclosporin A
Number of subjects: 229
Study: 16301723

Group type: EXPERIMENTAL
Intervention: First-trimester ultrasound examination; mean duration 8.9 minutes, mean MI 0.73 (range 0.3-1.3), mean TI 0.34 (0.1-1.7).
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Second-trimester ultrasound examination; mean duration 31.8 minutes, mean MI 1.04 (0.5-1.5), mean TI 0.28 (0.1-2.4).
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Third-trimester ultrasound examination; mean duration 16.3 minutes, mean MI 1.06 (0.2-1.5), mean TI 0.32 (0.1-2.4).
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Color Doppler imaging during third-trimester examinations; brief changes in TI observed.
Number of subjects: 37
Study: 11996956

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Pravastatin (20 mg initially, increased to 40 mg if necessary)
Number of subjects: 79
Study: 10434236

Group type: EXPERIMENTAL
Intervention: Lornoxicam 16 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Tramadol 100 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Lornoxicam (8 mg tid for 3 days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Tramadol (100 mg tid for 3 days)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 76
Study: 7776115

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination of diazepam and acetaminophen
Number of subjects: 180
Study: 1972011

Group type: EXPERIMENTAL
Intervention: Clenbuterol (40 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mabuterol (50 micrograms)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fenoterol (5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no beta-adrenergic agonist)
Number of subjects: 10
Study: 112656

Group type: EXPERIMENTAL
Intervention: ketotifen (1 mg twice daily)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: disodium cromoglycate (20 mg four times daily)
Number of subjects: 7
Study: 27749811

Group type: EXPERIMENTAL
Intervention: Web-based module (WBM)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Read-only website (ROW)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 233
Study: 29499082

Group type: EXPERIMENTAL
Intervention: Traditional herbal medicine (THM)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 364
Study: 26601786

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control
Number of subjects: 101
Study: 23810626

Group type: EXPERIMENTAL
Intervention: Go4it group treatment
Number of subjects: 122

Group type: COMPARATOR
Intervention: Current regular care (control)
Number of subjects: 122
Study: 22842422

Group type: EXPERIMENTAL
Intervention: One-stage reconstruction with a round permanent expander implant (Becker 25)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Two-stage reconstruction with a crescent-shaped expander (LV 133)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Quality of life evaluation using the 36-Item Short Form Health Survey
Number of subjects: 40
Study: 20085534

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) 20 mg/day for 3 weeks, then up-titrated to OM 40 mg/day for 3 weeks, and subsequently to OM/HCTZ 40/12.5 mg/day or OM/HCTZ 40/25 mg/day as necessary
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) + Hydrochlorothiazide (HCTZ)
Number of subjects: 192
Study: 17073853

Group type: EXPERIMENTAL
Intervention: Dexpanthenol pastille (200 mg, two pastilles sucked 30 min before operation)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Benzydamine hydrochloride spray (four puffs, sprayed 30 min before operation and 5 min before anaesthesia induction)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Distilled water (four puffs, sprayed 30 min before operation)
Number of subjects: 180
Study: 15764945

Group type: EXPERIMENTAL
Intervention: Immediate loading of two single‐standing titanium screw implants with cortical satellite implants and overdentures
Number of subjects: 20
Study: 17805122

Group type: EXPERIMENTAL
Intervention: Progressive tension sutures alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Drains alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Progressive tension sutures and drains
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no drains, no progressive tension sutures)
Number of subjects: 60
Study: 11053710

Group type: EXPERIMENTAL
Intervention: I-123 MIBG SPECT segmental uptake defects
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Mean areas of reduced LV I-123 MIBG uptake
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion defects (reversible, fixed, and paradox)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Topographic association between perfusion, innervation, and wall motion abnormalities
Number of subjects: 55
Study: 8997168

Group type: EXPERIMENTAL
Intervention: IVIG-and-aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin-alone
Number of subjects: 0
Study: 1637763

Group type: EXPERIMENTAL
Intervention: Chorion Villus Sampling (CVS)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 160
Study: 6712863

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30824398

Group type: EXPERIMENTAL
Intervention: Resistance exercises 2 days/week and aerobic exercises 1 day/week for 9 months with isoenergetic supplements containing 0, 10, 20, or 30 g whey protein twice daily
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Increases in lean mass
Number of subjects: 152
Study: 29399800

Group type: EXPERIMENTAL
Intervention: Alginos Oral Suspension (sodium alginate 1,000 mg three times daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alginos Oral Suspension
Number of subjects: 80
Study: 27090863

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 μg single injection)
Number of subjects: 1390

Group type: COMPARATOR
Intervention: Recombinant FSH (300 IU daily for 7 days)
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa and Recombinant FSH
Number of subjects: 1390
Study: 25049403

Group type: EXPERIMENTAL
Intervention: 7-week psychosocial intervention focused on improving parenting, strengthening family relationships, and building youth competencies.
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control condition (not specified).
Number of subjects: 272
Study: 23036134

Group type: EXPERIMENTAL
Intervention: Anticholinergic therapy (solifenacin 5 mg initially, possible escalation to 10 mg, switch to trospium XR 60 mg)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (100 U injection)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Anticholinergic therapy
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 249
Study: 21175515

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 18485759

Group type: EXPERIMENTAL
Intervention: Carotid Angioplasty/Stenting (CAS)
Number of subjects: 3227

Group type: COMPARATOR
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 3227
Study: 15851366

Group type: EXPERIMENTAL
Intervention: Immunonutrition (enteral formula enriched with glutamine, arginine, and omega-3 fatty acids)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard nutrition (standard enteral formula)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 40
Study: 14616431

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of dexmedetomidine (2 microg x kg-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Buccal administration of dexmedetomidine (2 microg x kg-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Peroral administration of dexmedetomidine (2 microg x kg-1)
Number of subjects: 12
Study: 10842420

Group type: EXPERIMENTAL
Intervention: 1.47 g protein/kg body cell mass/d (marginal diet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2.94 g protein/kg body cell mass/d (adequate diet)
Number of subjects: 12
Study: 8707238

Group type: EXPERIMENTAL
Intervention: 0.125 mg brotizolam
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 0.250 mg brotizolam
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 1521686

Group type: EXPERIMENTAL
Intervention: Direct evaluation using USPHS method
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Indirect evaluation using M‐L scale
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: USPHS evaluation system category of anatomic form
Number of subjects: 202
Study: 31772100

Group type: EXPERIMENTAL
Intervention: Outpatient care (discharge on the day of surgery, within 6-8 hours)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Inpatient care (hospital stay for 1-3 nights after surgery)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 104
Study: 28439987

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tadalafil 5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silodosin (after switching from Tadalafil)
Number of subjects: 0
Study: 25546001

Group type: EXPERIMENTAL
Intervention: Tafamidis 400 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 42
Study: 23630016

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Famotidine 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pantoprazole 20 mg
Number of subjects: 0
Study: 21646583

Group type: EXPERIMENTAL
Intervention: Peer-led asthma self-management program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional adult-led asthma program
Number of subjects: 112
Study: 19057407

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 16

Group type: COMPARATOR
Intervention: REST (passive sitting for 3 minutes)
Number of subjects: 16
Study: 16891338

Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentanoic acid (ethyl-EPA) 2 g per day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15060235

Group type: EXPERIMENTAL
Intervention: Cycled lighting (239 +/- 29 lux, 7:00 AM to 7:00 PM; <25 lux, 7:00 PM to 7:00 AM; duration: 25 days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Continuous dim lighting (<25 lux; duration 24 days)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cycled lighting
Number of subjects: 62

Group type: COMPARATOR
Intervention: Continuous dim lighting
Number of subjects: 62
Study: 11509461

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) self-help programme; 6 months follow-up
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 229
Study: 9586828

Group type: EXPERIMENTAL
Intervention: Active medication (beta-carotene 15 mg, vitamin C 150 mg, vitamin E 75 mg, selenium 101 microg, calcium 1.6 g daily)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 7922794

Group type: EXPERIMENTAL
Intervention: rectal salmon calcitonin (sCT), 100 IU daily (n = 25)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: nasal salmon calcitonin (sCT), 200 IU daily (n = 17)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (18 age‐matched women who received no treatment)
Number of subjects: 42
Study: 3044871

Group type: EXPERIMENTAL
Intervention: Cefatrizine 75 mg/kg.day once daily for 8 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefatrizine 75 mg/kg.day twice daily for 8 days
Number of subjects: 30
Study: 29143388

Group type: EXPERIMENTAL
Intervention: No core material
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amalgam core
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Composite resin core
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (unrestored)
Number of subjects: 60
Study: 27523961

Group type: EXPERIMENTAL
Intervention: Verum (egg white powder)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo (rice powder)
Number of subjects: 383
Study: 25904376

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 328
Study: 23829621

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with house dust mite (HDM) extracts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21138505

Group type: EXPERIMENTAL
Intervention: Low-frequency (1 Hz) rTMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham placebo
Number of subjects: 12
Study: 19266214

Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (SE)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 62
Study: 16505512

Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 1063

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 1063
Study: 15295345

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape
Number of subjects: 344

Group type: COMPARATOR
Intervention: Colposuspension
Number of subjects: 344
Study: 11399214

Group type: EXPERIMENTAL
Intervention: Daily maintenance doses of 4 mg/70 kg (n = 14) or 8 mg/70 kg (n = 19) of liquid buprenorphine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Triple the daily maintenance dose every 72 hours (12 or 24 mg/70 kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Quintuple the daily maintenance dose every 120 hours (20 or 40 mg/70 kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Open-dosing procedures with three dosing regimens
Number of subjects: 33
Study: 9399274

Group type: EXPERIMENTAL
Intervention: Breast self-examination facilitation shield
Number of subjects: 52

Group type: COMPARATOR
Intervention: No breast self-examination facilitation shield (control)
Number of subjects: 52